Drew Lewis, MD, MTM&H

Vice President, Clinical Development
Entasis Therapeutics

Disclosure(s): Entasis Therapeutics: employee, employee, Stocks/Bonds, Stocks/Bonds

Poster(s):

• 225 - Efficacy and safety of sulbactam-durlobactam are consistent across regions in the global ATTACK phase 3 trial in the treatment of carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRABC) infections
  Thursday, October 20, 2022

  12:15 PM – 1:30 PM US ET

• 675 - Sulbactam-durlobactam (SUL-DUR) versus colistin therapy in patients with Acinetobacter baumannii-calcoaceticus complex (ABC) infections: A detailed safety review from the pivotal phase 3, global, randomized, active-controlled trial (ATTACK)
  Thursday, October 20, 2022

  12:15 PM – 1:30 PM US ET